![National COVID Cancer Survey image](/sites/default/files/styles/square_card_l/public/media/images/media-3178.jpg.webp?itok=N_FBSkl9)
The National COVID Cancer Antibody Survey
There's still time to sign up to have your COVID antibody levels tested and help scientists work out what level of antibodies offers protection against COVID-19.
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
There's still time to sign up to have your COVID antibody levels tested and help scientists work out what level of antibodies offers protection against COVID-19.
New guidelines give clear treatment recommendations for people with T-cell and NK-cell lymphomas
The UK’s Medicines & Healthcare products Regulatory Agency (MHRA) has approved tafasitamab, combined with lenalidomide, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who can’t have a stem cell transplant.
2021 was a special year for Lymphoma Action, as we marked our 35 year anniversary!
Thank you for your support during 2021 - we're sending best wishes for the coming year.
In our latest podcast our Patron, Lord Menzies Campbell, talks to us about his esteemed and varied career, how some of his greatest achievements have been since his diagnosis of non-Hodgkin lymphoma in 2002.
Order or download our new book, Chronic lymphocytic leukaemia and small lymphocytic lymphoma.
Ibrutinib monotherapy has been approved for NHS in Scotland for adults with Waldenström’s macroglobulinaemia who have had at least one previous course of treatment.
Simran’s family have raised an amazing £51,644 to support our work.
The paper covers recommendations on the diagnosis and treatment of people with Richter transformation.